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Abstract
Background: Determining the presence and extent of co-morbidities is fundamental in assessing patients with
chronic respiratory disease, where increased cardiovascular risk, presence of osteoporosis and low muscle mass
have been recognised in several disease states. We hypothesised that the systemic consequences are evident in a
further group of subjects with COPD due to Alpha-1 Antitrypsin Deficiency (A1ATD), yet are currently under-
recognised.
Methods: We studied 19 patients with PiZZ A1ATD COPD and 20 age, sex and smoking matched controls, all
subjects free from known cardiovascular disease. They underwent spirometry, haemodynamic measurements
including aortic pulse wave velocity (aPWV), an independent predictor or cardiovascular risk, dual energy X-ray
absorptiometry to determine body composition and bone mineral density.
Results: The aPWV was greater in patients: 9.9(2.1) m/s than controls: 8.5(1.6) m/s, p = 0.03, despite similar mean
arterial pressure (MAP). The strongest predictors of aPWV were age, FEV1% predicted and MAP (all p < 0.01).
Osteoporosis was present in 8/19 patients (2/20 controls) and was previously unsuspected in 7 patients. The fat
free mass and bone mineral density were lower in patients than controls (p < 0.001).
Conclusions: Patients with A1ATD related COPD have increased aortic stiffness suggesting increased risk of
cardiovascular disease and evidence of occult musculoskeletal changes, all likely to contribute hugely to overall
morbidity and mortality.
Background
The systemic manifestations in chronic respiratory con-
ditions such as chronic obstructive pulmonary disease
(COPD) can be multiple and include a persistent sys-
temic inflammatory state, excess cardiovascular disease,
bone thinning and low skeletal muscle mass; each asso-
ciated with considerable morbidity and mortality [1-3].
Alpha-1 antitrypsin deficiency (A1ATD) is an estab-
lished genetic risk factor estimated to occur in 1-2% of
patients with COPD, though generally under-recognised
and the co-morbidities in this condition have not
explored [4]. Characterisation of the genetic and proteo-
nomic basis of the A1ATD status has supported the
protease-antiprotease theory of lung injury, as abnor-
mally low levels of alpha-1 antitrypsin (A1AT) leads to
unopposed protease activity and destruction of the elas-
tin matrix within the lung, resulting in emphysema. In
usual COPD, the emphysematous extent has been
related to the cardiovascular and bone alterations [5,6].
In addition to its presence in the lungs, circulating
A1AT also binds to the endothelium [7], has a protective
role in limiting vascular damage and is involved in the
regulation of vascular smooth muscle cells and control of
inflammatory pathways [8,9]. Low levels of A1AT, lead-
ing to unopposed neutrophil elastase activity in the vas-
culature may result in the local degradation of elastin,
with a resultant increased collagen deposition. In the lar-
ger central arteries, the elastin:collagen balance is an
important structural contribution in determining arterial
stiffness, which is implicated in arteriosclerosis and sub-
sequent cardiovascular risk [10,11]. The current literature
on cardiovascular risk in the PiZZ A1ATD is conflicting,
largely due to small sized studies or sub-analysis of this
homozygous state in larger studies [12-14].
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Previously, we have demonstrated increased aortic
stiffness, low bone mineral density (BMD) and low ske-
letal muscle mass in the presence of a heightened circu-
lating inflammatory state in patients with usual COPD
[15,16]. We hypothesised that these cardiovascular and
musculoskeletal systemic co-morbidities would be pre-
sent in the chronic respiratory disease A1ATD and
hence need to be identified.
Materials and methods
Study Subjects
Adult patients with PiZZ A1ATD and confirmed airways
obstruction or CT proven emphysema on the ADAPT
(Antitrypsin Deficiency Assessment and Programme for
Treatment) register residing within a 1.5 hour commuta-
ble distance of the Cardiff study centre, together with
patients from respiratory out-patients clinics were
invited. Patients were studied when clinically stable [15].
Sedentary control subjects, matched for age, sex, smoking
and additionally free of respiratory disease were also
recruited from the same region. Exclusion criteria for all
subjects included malignancy, rheumatoid disease, dia-
betes mellitus, maintenance oral corticosteroids, active
infection or other chronic inflammatory disease, weight
losing drugs, known congestive heart failure, documented
history of cardiovascular disease, solid organ transplanta-
tion, parallel participation in interventional study, preg-
nancy or breastfeeding. All subjects gave written,
informed consent and the study had South West Wales
Research Ethics Committee approval (08/WMW02/48).
Anthropometry, Lung Function and Physical function
Height and weight (Seca, Germany) were determined
barefoot and in lightweight indoor clothing and the
body mass index (BMI) calculated. A low BMI was
defined as <20 kg/m2 [15].
All subjects performed spirometry: forced expiratory
volume in 1 second (FEV1), forced vital capacity (FVC),
and FEV1/FVC ratio, (Vitalograph Ltd, Bucks UK) having
withheld short- and long-acting bronchodilators for six
and twelve hours respectively. Subjects underwent a six
minute walk test (6MWD) after all other assessments had
been performed [17]. All patients completed a St George
Respiratory Questionnaire (SGRQ) and all subjects com-
pleted a physical activity questionnaire relating to their
last month’s activity [18,19]. Contemporaneous room air
arterialised ear lobe gases were determined in the patients.
Recent (within 12 months) post bronchodilator lung
volumes and gas transfer data were obtained from
patients’ medical notes and, if not, were performed (n = 3).
Cardiovascular measurements
Subjects were studied after an overnight fast and 6
hours after abstinence from caffeine, tobacco, and
inhaled short-acting b2 agonists and 12 hours following
long-acting b2 agonists, to ensure haemodynamic mea-
sures were made free of the acute effect of these
agents [16]. All tests were performed after ten minutes
of supine rest. Peripheral blood pressure (BP) was
measured in the dominant arm (OMRON Corporation,
Japan). Radial artery waveforms were recorded via a
high fidelity micro manometer (Millar Instruments,
Texas). Pulse wave analysis (Syphgmocor, AtCor Medi-
cal, Australia) was subsequently used to derive a heart
rate adjusted augmentation index (AIx-75). Aortic (car-
otid-femoral) pulse wave velocity (aPWV) was mea-
sured as previously described [10,16]. Traces were
assessed by an independent reviewer, blinded to the
subject status.
Dual-Energy X-ray Absorptiometry (DXA)
Whole body composition and BMD at the lumbar spine
and hip (and 3 hip subregions) were determined, within
3 weeks of the main study visit, using Hologic Discovery
(Hologic, MA) [15]. The FFM, indicative of skeletal mus-
cle mass was expressed as a height squared ratio to give
an index: FFMI. A low FFMI was defined as < lower 5th
percentile for controls [15]. Upper limb (both), lower
limb (both) and trunk FFMI were calculated using anato-
mical markers [20]. Osteoporosis was defined as T score
less than -2.5 and osteopenia as T score less than -1 but
greater than -2.5 [21].
Biochemistry, bone markers and inflammatory mediators
An early morning, fasted venous blood sample was col-
lected. Testosterone (men only), thyroid function tests
(TFT’s), parathyroid hormone (PTH) and insulin were
measured using immunoassay (ADVIA Centaur).
25-hydroxy (OH)-Vitamin D was measured using direct
competitive luminescence (Diasorin Liason). Corrected
calcium, creatinine, fasting glucose and lipids (choles-
terol, High Density Lipoprotein [HDL], Low Density
Lipoprotein [LDL] and triglycerides) were measured
using two site immunoassay (Abbot Diagnostics,
Berkshire). IL-6 was measured using Quantikine immu-
noassay (R&D Systems Inc, MN, USA), as previously
reported [15].
Data Analysis
Data analysis was performed using the Statistical Pack-
age for the Social Sciences (SPSS, Chicago, IL), version
12.0. Log10 transformation was used where data was not
normally distributed. Results are presented as arithmetic
or geometric mean and standard deviation (SD).
Analyses included c2 test, independent t test, Pearson’s
correlations, one-way analysis of variance with post hoc
Tukey analysis, and stepwise multiple regression analy-
sis. A p < 0.05 was considered significant.
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Sample size was based on our primary outcome of
aPWV, using data for patients with COPD. 18 patients
were required per group in order to detect a 15% differ-
ence in aPWV between groups, with a SD of 2 m/s, a
significance of 0.05 and a power of 0.8.
Results
Subjects
Of the total 49 patients with PiZZ A1ATD approached,
23 agreed to be contacted and fulfilled the initial screen
of suitability, but three were subsequently excluded after
further discussion: due to known ischaemic heart disease
(n = 2) and active Hepatitis C infection (n = 1). Of the
20 patients recruited, one developed chest pains necessi-
tating investigation prior to study commencement and
he was excluded. Thus, 19 A1ATD patients and 20 con-
trols were studied.
Patients and controls were similar in terms of age, sex,
height and smoking pack year history, (Table 1). Of the
patients, four had never smoked and five smoked less
than 10 pack years and one was a current smoker. Of
the control subjects, three had never smoked and eight
smoked less than ten pack years and two were current
smokers.
Of the patients, 17 were prescribed combination long
acting b2 agonist/inhaled corticosteroid (median steroid
dose 2000 mcg betamethasone equivalent). Inhaled
anticholinergics were prescribed to 16 patients. Three
patients had a prior diagnosis of osteoporosis and were
receiving bisphosphonate therapy. There were four
patients and three controls with a prior diagnosis of
hypertension. Three patients and three controls had a
prior history of hypercholesterolaemia. The median
(range) alpha 1 antitrypsin levels in patients was 3.1
(1.7-8.6)μmol/L
Pulmonary and physical function tests
As expected, the patients had a lower FEV1, FVC and a
shorter 6MWD than the controls, (p < 0.001), (Table 1).
Two patients had a resting PaO2 on room air <7.3 kPa.
Cardiovascular data
There was no difference in heart rate, peripheral or cen-
tral systolic, diastolic BP or mean arterial pressure
(MAP) between patients and controls, Table 2. Mean
(SD) aPWV was greater in patients: 9.9(2.2)m/s than
controls: 8.5(1.6)m/s, p = 0.03). AIx-75 was not differ-
ent, p = 0.33, (Table 2). The aPWV was greater in males
than females overall, p < 0.001 as well as in each group.
We found increased aPWV in patients with A1ATD
compared to controls by at least 0.7 m/s (and upto 1.8
m/s) for each decade in the overlapping age range, how-
ever small numbers per group preclude formal analysis
to determine significance. In all subjects, aPWV was
associated with age (r = 0.56, p < 0.001) and Log10IL-6
(r = 0.50, p = 0.001) and was inversely related to FEV1%
predicted (r = -0.43, p = 0.006), FVC% predicted (r =
-0.42, p = 0.007) and physical activity scores (r = -0.36,
p = 0.02).
Stepwise linear regression in all subjects with aPWV
as the dependent variable and age, sex, FEV1% predicted,
peripheral MAP, heart rate, log10IL-6 and smoking pack
Table 1 Subject demographics, pulmonary function and
body composition
Controls
n = 20
Patients
n = 19
P value
Age (years) 61.1 (9.1) 59.2 (12.1) 0.59
Men n (%) 13 (65%) 12 (63%)
Smoking pack year* 5.5 (0-70) 10.0 (0-60) 0.69
FEV1 (% predicted) 100.8 (12.5) 42.7 (23.3) <0.001
FVC (% predicted) 106.7 (17.5) 87.2 (25.6) 0.008
TLCO (mmol/min/kPa) ND 4.1 (1.3)
Oxygen saturation (%) 97 (1) 92 (4) 0.008
PaO2 (kPa)* ND 8.9 (2.0)
6 MWD (m) 497 (80) 312 (133) <0.001
Height (m) 1.69 (0.06) 1.71 (0.10) 0.42
Weight (kg) 80.5 (14.8) 69.4 (12.0) 0.014
BMI (kg/m2) 28.3 (4.0) 23.7 (3.0) 0.001
FFMI (kg/m2) 18.6 (2.6) 15.7 (1.7) <0.001
SGRQ - total ND 52.0 (15.2)
Physical activity score 40 (9) 33 (5) 0.006
All data represented as mean (standard deviation) unless otherwise indicated
*median (range)
Abbreviations: FEV1 Forced Expiratory Volume 1 second, FVC Forced Vital
Capacity, TLCO Total Lung Carbon Monoxide Transfer Factor, PaO2 Arterial
oxygen tension, 6MWD 6 Minute Walk Distance, BMI Body mass Index, FFMI
Fat Free Mass Index, SGRQ St Georges Respiratory Questionnaire
ND not determined
Table 2 Subject haemodynamics
Control
n = 20
Patient
n = 19
P value
Heart rate (bpm) 68 (12) 76 (13) 0.07
Peripheral systolic BP (mmHg) 136.9 (14.9) 130.3 (14.3) 0.17
Peripheral diastolic BP (mmHg) 82.7 (6.9) 84.6 (7.5) 0.40
Peripheral MAP (mmHg) 100.4 (10.2) 101.5 (9.2) 0.72
Peripheral PP (mmHg) 54.2 (16.6) 45.7 (12.0) 0.08
Central Systolic
pressure (mmHg)
126.5 (14.5) 121.1 (14.5) 0.26
Central diastolic
pressure (mmHg)
84.3 (7.1) 85.8 (7.5) 0.53
Central MAP (mmHg) 102.0 (7.5) 101.5 (9.2) 0.86
Central PP (mmHg) 43.0 (15.6) 35.2 (10.8) 0.08
aPWV (m/s) 8.5 (1.6) 9.9 (2.1) 0.03
AIx-75 23.7 (8.8) 26.1 (6.5) 0.33
Abbreviations:
MAP Mean arterial pressure, PP pulse pressure, aPWV aortic pulse wave
velocity, AIx-75 Augmentation index corrected to heart rate 75 beats per
minute
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years inputted as independent variables, demonstrated
that the predictors were age (R2 = 0.30, p < 0.001),
FEV1% predicted (R
2 = 0.23, p = 0.001), peripheral MAP
(R2 = 0.08, p < 0.001) and heart rate (R2 = 0.09,
p = 0.002).
Body composition
The mean BMI was lower in patients than controls (p =
0.001) (Table 1), and 2 patients had a pathologically low
BMI (no controls). The 2 patients with a low BMI also
had low FFMI and 6 other patients had a low FFMI
with normal BMI, indicating hidden FFM loss. The
FFMI was globally lower including upper limbs (p =
0.01), lower limbs (p < 0.001) and trunk (p = 0.001) of
patients compared to controls. In the whole study popu-
lation, FFMI was related to FEV1%predicted (r = 0.40,
p = 0.01) and 6MWD (r = 0.46, p = 0.003).
Bone mineral density and osteoporosis
The BMD at the total hip site, all three hip sub-regions
and the lumbar spine were all less in the patients than
controls (p < 0.001), (Table 3). In all subjects, FEV1%
predicted was related to total hip BMD (r = 0.60, p <
0.001) and lumbar spine (r = 0.55, p < 0.001). Similarly,
FFMI was related to the total hip BMD (r = 0.67, p <
0.001) and lumbar BMD (r = 0.61, p < 0.001).
Multiple regression analyses with total BMD at either
the lumbar spine or hip as the dependent variables and
age, sex, FEV1% predicted, FFMI as independent vari-
ables were performed. At both the hip and the lumbar
spine, FFMI, (adjusted R2 = 0.43, p < 0.001 and R2 =
0.35, p < 0.001 respectively) was the only predictive
variable.
There were eight patients and two controls with a
clinical diagnosis of osteoporosis at either site. Seven of
the eight patients and both the controls were new diag-
noses of osteoporosis and not previously clinically sus-
pected, necessitating initiation of therapy. Two further
patients on prior bisphosphonate therapy were no
longer classified as osteoporotic on DXA scan, although
still osteopenic. In total, there were 8 A1ATD patients
and 4 controls who were osteopenic. There was no
difference in FFMI, FEV1% predicted, 6MWD and
aPWV between those patients with osteoporosis or not.
Biochemistry and systemic inflammation
In order to determine other factors that might influence
osteoporosis, we explored TFT’s, testosterone, 25-OH
vitamin D and PTH levels. No subject had abnormal
TFT’s and no male subject had low early morning tes-
tosterone levels (< 8.0 nmol/L), (Table 4).
Insufficient 25-OH vitamin D levels (< 20 μg/l) (21)
were recorded in 12 patients and 12 controls. Of these,
three patients and two controls had low 25-OH vitamin
D levels (< 10 μg/l), (Table 3) [22].
Elevated PTH levels (all with normal calcium and
creatinine levels) were recorded in 9 patients and 10 of
the controls. Of these, elevated PTH levels in conjunc-
tion with low 25-OH Vitamin D levels but normal cal-
cium levels were seen in five patients and eight controls.
All patients with A1ATD had normal liver function
tests. There were 7 patients and 7 controls with total
fasting cholesterol >6.2 mmol/l, and one patient had an
impaired fasting glucose of > 6.0 mmol/l. Circulating
IL-6 was greater in patients: (3.24(1.62) than controls:
2.18(1.62) pg/ml, p = 0.016).
Discussion
This study demonstrates, for the first time, that patients
with COPD due to alpha 1 antitrypsin deficiency have
increased aortic stiffness, as determined by aPWV, com-
pared to age and sex matched controls despite a similar
risk profile including blood pressure, fasting lipids, glu-
cose and a comparatively low smoking pack year expo-
sure. This indicates increased cardiovascular risk in this
group of subjects with A1ATD with established chronic
lung disease that would not have been detected on stan-
dard peripheral sphygmomanometry. In addition,
patients with A1ATD had lower BMD than matched
Table 3 Subject bone mineral density and profile
Control
n = 20
Patient
n = 19
P value
BMD Hip (g/cm2) 1.03 (0.20) 0.79 (0.12) <0.001
BMD Lumbar spine (g/cm2) 1.12 (0.20) 0.88 (0.13) <0.001
PTH (pmol/l) 5.26 (1.88) 5.53 (2.00) 0.67
25-OH Vitamin D (μg/l) 18.0 (8.6) 19.5 (9.0) 0.62
All data represented as mean (standard deviation) unless otherwise indicated
# geometric mean
Abbreviations
BMD Bone Mineral Density, PTH parathyroid hormone 25-OH 25 hydroxy
Table 4 Biochemistry and Systemic Inflammatory status
Control
n = 20
Patient
n = 19
P value
Total cholesterol (mmol/l) 5.8 (1.0) 5.7 (1.4) 0.66
HDL (mmol/l) 1.6 (0.3) 1.7 (0.5) 0.44
LDL (mmol/l) 3.7 (1.0) 3.5 (1.2) 0.58
Triglycerides # (mmol/l) 1.19 (0.49) 0.98 (0.31) 0.12
Fasting Glucose (mmol/l) 5.2 (0.6) 4.9 (0.5) 0.06
Creatinine (μmol/l) 88.4 (18.1) 84.0 (12.6) 0.39
eGFR (mls/min/1.73 m2) 75.9 (15.6) 79.4 (12.1) 0.44
Testosterone(males)nmol/l # 15.6 (1.2) 24.6 (1.4) 0.001
IL-6 (pg/ml)# 2.18 (1.62) 3.24 (1.62) 0.016
All data represented as mean (standard deviation) unless otherwise indicated,
# geometric mean
Abbreviations: HDL High Density Lipoprotein, LDL Low density Lipoprotein,
eGFR Estimated Glomerular Filtration Rate; IL-6 Interleukin 6
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controls with a significant proportion having a new
diagnosis of osteoporosis despite none receiving mainte-
nance oral corticosteroids. Patients had lower BMI and
FFMI than controls with nearly half the patient group
having skeletal muscle mass loss [15].
The study has highlighted a number of potential
mechanisms for these changes. As in usual COPD
where systemic manifestations have been explored in
more detail, it is possible that the heightened systemic
inflammatory state, physical inactivity and impaired
muscle function may have a role in the development of
the systemic manifestations [15,16]. However, in addi-
tion, the systemic protease-antiprotease imbalance, at
the core of A1ATD, is a possible central factor.
The increased systemic inflammatory state in the
patients, when clinically stable and heightened at times
of exacerbation may be a mechanism of the altered
large artery haemodynamics [15,23]. This relationship
corresponds to the literature between systemic inflam-
mation and cardiovascular risk in both the general
population and in patients with COPD [16,24]. Inflam-
mation is associated with endothelial dysfunction but
may also promote arterial stiffness by direct effects on
vessel architecture and vascular smooth muscle function
[25-27]. The association of A1AT with inflammatory
and coagulation pathways and the A1AT link to HDL
and its functional properties are interesting considera-
tions suggesting a pleiotropic beneficial effect of A1AT,
which the deficient state exposes [8,9,28].
Importantly, the A1AT deficiency may have a direct
effect on the elastin of the larger arteries, leading to
altered structure and function. Talmud et al. described a
protective role for A1AT in the progression of estab-
lished coronary artery atherogenesis, based on angiogra-
phy and the genotyping of 800 subjects in 2 clinical trials
[13]. Indeed, Aldonyte et al. demonstrated that A1AT is
taken up by pulmonary endothelial cells using in vitro
porcine cultures and appears to have a protective role
against cigarette smoke induced endothelial apoptosis
[29]. Similarly, the transformational polymerisation of
AAT in A1ATD subjects, present not just in hepatocytes
but circulating and in the lung and systemic endothelium
are pro-inflammatory and inactivate the protein as an
inhibitor of proteases (thereby reducing any anti-protease
protection further) and hence may be contributory to the
altered haemodynamics [30,31]. Indeed, such a protease -
antiprotease imbalance mechanism may account for the
cross-sectional association of emphysema severity (using
CT) with both low BMD and increased arterial stiffness
in usual COPD [5,6]. However, in these COPD studies,
knowledge and quantification of protease - antiprotease
activity and level are not described. Interestingly, McAll-
ister et. al. reported that emphysema severity was an
independent variable, over airways obstruction and the
systemic inflammatory mediator CRP, for brachial PWV
in patients with usual COPD [5]. It is conceivable that a
systemic proteolytic process is occurring in the emphyse-
matous spectrum of COPD including A1ATD subjects
affecting arterial wall structure; however conclusive proof
either way is beyond the scope of this study.
Increased aortic distensibilty, a suboptimal measure of
arterial stiffness, has been reported in a small number of
male patients with A1ATD but not the female subset
where the authors sought to assess the risk of aortic
aneurysms [12]. The use of historical controls and the
wide age range from early adulthood limits its interpre-
tation. Meanwhile, other reports have postulated that
A1ATD may actually be associated with a reduced risk
of ischaemic heart disease and lower BP, however sub-
ject numbers were low, especially of the homozygous
PiZZ genotype, n = 6 [32].
Increased arterial stiffness, measured by aPWV confers
an increased and independent cardiovascular risk
[10,11]. This has been firmly established through a
wealth of studies in both general populations and var-
ious at-risk disease groups [8]. Addressing central hae-
modynamic measurements have become key outcome
measures in cardiovascular studies, as alterations in
large artery haemodynamics may not be detected using
only standard peripheral measurements [33,34]. The
clinical relevance of this increased cardiovascular risk is
demonstrated by the high cardiovascular mortality seen
in COPD patients in general [3,35]. Patients with
A1ATD often present at a younger age than usual
COPD and indeed, here, the subjects were about 5 years
younger than subjects in previously reported usual
COPD studies, which have previously excluded A1ATD.
Despite this younger age group, the patients with
A1ATD have striking systemic consequences and may
well reflect an accelerated ageing process [36,37]. The
extent of these systemic consequences in usual COPD
has only recently been prioritised and we now highlight
in A1ATD. Optimisation of risk factors is imperative
and exercise regimes or pulmonary rehabilitation may
offer additional improvement in any functional altera-
tion leading to arterial stiffness [38]. The similar results
for AIx-75 between the 2 groups are in keeping with the
non-linear relationship with age of this measure, which
plateaus over the age of 50 years and hence deemed less
sensitive to change in this age group.
The mechanism of low BMD in these patients is simi-
larly likely to be due to several mechanisms. Some
patients had been exposed to short courses of oral corti-
costeroids although none were on maintenance therapy.
Previously, we have reported a lower BMD occurs in
patients with usual COPD even if steroid naïve suggest-
ing other “COPD related factors” are likely to be addi-
tional key factors [39]. In this current study, Vitamin D
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levels were low across both patients and controls suggest-
ing it may play only a limited or no additional role. To
allow for seasonal variation in Vitamin D, all subjects
were studied during winter period. Like cardiovascular
disease, a low BMD may be related to the circulating
inflammation but additionally to deconditioning as evi-
denced by the low FFM, the shorter 6MWD and lower
physical activity scores seen in these patients compared
to controls. Interestingly, however, the FFMI was globally
low throughout all the body regions and not confined to
lower limbs. Previously we have reported that patients
with usual COPD with osteoporosis had elevated aPWV
[16], however the current study was not powered for
such an outcome and description of the co-morbidities
was our primary aim.
Limitations of study
The study size is small due to difficulty in recruiting eli-
gible Pi ZZ A1ATD patients within a commutable dis-
tance of the research centre. The comprehensive
exclusion criteria prevented other confounders, such as
diabetes or known cardiovascular disease from exagger-
ating or affecting the primary aim of identifying the hid-
den co-morbidities. Collaboration with ADAPT ensured
the sample size was sufficient to achieve our aims based
on the power calculation. A proportion were ex or cur-
rent smokers, albeit more modest exposure than usual
COPD patients. This is inevitable given smoking
remains the trigger that precipitates the emphysematous
change in A1ATD and hence presentation to physicians.
Emphysema index was not measured universally in sub-
jects and hence not included.
The cross sectional nature of the study does not allow
causal relationships between A1ATD, arterial stiffness,
low BMD and systemic inflammation to be inferred but
does show relationships that would suggest that further
longitudinal studies may be informative and highlights a
priority for full assessment of the co-morbidities in
patients with A1ATD. Lastly, the presence of such
extrapulmonary manifestations in patients with the het-
erozygote state remains to be explored and may indicate
whether the presence of the Z protein alone plays a role
rather than the low A1AT level.
In conclusion, patients with COPD related to PiZZ
A1ATD had increased aortic stiffness compared with age
and gender matched controls without chronic lung dis-
ease, despite the similar risk profiles such as smoking,
blood pressure and lipid levels. Such patients also had a
lower BMD with evidence of osteoporosis and a low ske-
letal muscle mass. There is thus a priority to explore
underlying mechanisms as to why patients COPD due to
A1ATD are at risk of these systemic consequences,
which are hugely under-recognised in clinical practice
but contribute to morbidity and necessitate optimal
management.
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